Bad Memo Day for Glaxo

The HeraldJune 07, 2004

Linked as:

Summary


BITTER PILL: GlaxoSmithKline is facing potential criminal prosecution in the UK for allegedly not informing health regulators about the risks of higher suicide rates among users of its flagship anti-depressant, Seroxat, writes Karl West.

The Medicines and Healthcare Products Regulatory Agency has launched an investigation into Glaxo over concerns that the drugs giant had withheld important information from clinical trials, according to reports.

See the full content of this document

Extract


Bad Memo Day for Glaxo

The suppressed data showed that Seroxat could cause an increased risk of suicide ...

See the full content of this document

Sponsored links




ver las páginas en versión mobile | web

ver las páginas en versión mobile | web

© Copyright 2012, vLex. All Rights Reserved.

Contents in vLex United Kingdom

Explore vLex

For Professionals

For Partners

Company